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Abstract
Aims: Patients with prior major cardiovascular or cerebrovascular events (MACE) are more likely to have future
recurrent events independent of traditional cardiovascular disease risk factors. The purpose of this study was to
determine if patients with traditional risk factors and prior MACE had increased cardiovascular magnetic
resonance (CMR) plaque burden measures compared to patients with risk factors but no prior events.
Methods and Results: Black blood carotid and thoracic aorta images were obtained from 195 patients using a
rapid extended coverage turbo spin echo sequence. CMR measures of plaque burden were obtained by tracing
lumen and outer vessel wall contours. Patients with prior MACE had significantly higher MR plaque burden (wall
thickness, wall area and normalized wall index) in carotids and thoracic aorta compared to those without prior
MACE (Wall thickness carotids: 1.03 ± 0.03 vs. 0.93± 0.03, p = 0.001; SD wall thickness carotids: 0.137 ± 0.0008
vs. 0.102 ± 0.0004, p < 0.001; wall thickness aorta: 1.63 ± 0.10 vs. 1.50 ± 0.04, p = 0.009; SD wall thickness aorta:
0.186 ± 0.035 vs. 0.139 ± 0.012, p = 0.009 respectively). Plaque burden (wall thickness) and plaque eccentricity
(standard deviation of wall thickness) of carotid arteries were associated with prior MACE after adjustment for
age, sex, and traditional risk factors. Area under ROC curve (AUC) for discriminating prior MACE improved by
adding plaque eccentricity to models incorporating age, sex, and traditional CVD risk factors as model inputs
(AUC = 0.79, p = 0.05).
Conclusion: A greater plaque burden and plaque eccentricity is prevalent among patients with prior MACE.
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Background
Atherosclerosis is a major cause of morbidity and mortal-
ity world-wide with the most serious outcomes being
myocardial infarction, stroke and death [1,2]. Atheroscle-
rosis affects all vascular beds, including the coronary,
carotid, aorta and peripheral arteries and is present years
before a cardiovascular event[3]. Surrogate measures of
atherosclerosis are increasingly being used as substitute
endpoints for clinical trials, with serum biomarkers and
imaging [4,5] being potential candidates for assessing
underlying disease [6,7]. Surrogate markers for atheroscle-
rosis if validated, might allow assessments of the effective-
ness of cardio-protective interventions at earlier time
points with significant savings in cost. It is also known
that patients with prior major cardiovascular and cere-
brovascular events (MACE) are at increased risk for recur-
rent events independent of other risk factors [8-10].
Atherosclerotic plaques have been imaged and certain
plaque characteristics may be associated with an increased
risk for cardiovascular events. For example, studies using
MRI have been used to image vulnerable plaques that
exhibit thin fibrous caps overlying large necrotic lipid
cores [11,12]. High-resolution cardiovascular magnetic
resonance (CMR) has also been shown to be capable of
identifying plaque constituents, such as the necrotic core
and intraplaque hemorrhage, in human carotid athero-
sclerosis [13].
Furthermore, although the underlying pathological proc-
esses might be similar in all vascular beds, there are other
important factors such as endothelial shear stress which
differ from one vascular bed to another [14,15]. Studies
have evaluated the degree to which measures of subclini-
cal atherosclerosis in multiple vascular beds correlate with
each other and have reported the risk factors associated
with atherosclerosis in each of these vascular beds [16].
Therefore, evaluating multiple vascular beds in an indi-
vidual might provide additional information regarding
their future risk for cardiovascular events.
The recent ENHANCE (Effect of Combination Ezetimibe
and High-Dose Simvastatin vs. Simvastatin Alone on the
Atherosclerotic Process in Patients with Heterozygous
Familial Hypercholesterolemia) clinical trial recently
compared the mean change in the intima-media thickness
(IMT) measured at three sites in the carotid arteries
between patients with heterozygous familial hypercholes-
terolemia treated with ezetimibe/simvastatin 10/80 mg
versus patients treated with high-dose simvastatin 80 mg
alone [17]. The results of this study may indicate that use
of carotid intima media thickness (IMT) as a surrogate
marker for rate of clinical events due to atherosclerosis
might not be ideal [18,19]. These results also indicate that
additional thrusts may be desirable towards pursuing
other surrogate markers for clinical endpoints due to
atherosclerotic disease and for creating end points for
clinical trials.
Although not currently used on a routine clinical basis,
black blood in-vivo non-invasive CMR [20,21] is an accu-
rate, highly reproducible technique for the imaging of the
arterial wall [22]. It is capable of measuring the total bur-
den of atherosclerotic disease in multiple vascular distri-
butions and has been suggested as a reliable outcome
measure in clinical trials[22] and epidemiological stud-
ies[23]. CMR findings have been extensively validated
against pathology in ex vivo studies of carotid, aortic, and
coronary artery specimens obtained at autopsy and using
experimental models of atherosclerosis[14]. CMR offers
unique advantages for the assessment of the carotid arter-
ies and the thoracic aorta for quantification of atheroscle-
rosis including the ability to provide highly reproducible
measures [24-27] of anatomy and atherosclerosis burden
without ionizing radiation.
The purpose of this study was to determine if we could
identify morphometric features of atherosclerosis in indi-
viduals with risk factors with and without prior MACE,
which confer the historically known higher risk for recur-
rent events. We also sought to test whether including such
CMR measures in a model for discriminating prior MACE
can improve discerning power beyond a model consisting
of demographics and traditional cardiovascular disease
(CVD) risk factors. If differences were found in CMR
plaque burden measures of the common carotid arteries
and descending thoracic aorta in patients with and with-
out prior MACE, this may provide preliminary informa-
tion for the use of these measures in prospective studies.
Results of this study might also help in evaluating CMR as
a modality to further screen patients prior to inclusion in
studies with clinical end points by reducing the number of
subjects required for adequate power.
Methods
This study was approved by the institutional review board
of the Mount Sinai School of Medicine and written
informed consent was obtained from all subjects. This
study also conformed to the Health Insurance Portability
and Accountability Act (HIPAA) guidelines.
Patient population
One hundred and ninety five patients aged 50 years or
older and with at least two risk factors for atherosclerosis
were recruited serially from January 2003 – December
2006 into the imaging study. Patients were recruited from
the offices of local physicians in the New York area and at
Mount Sinai Hospital. The local physicians screened
patients based on their traditional risk factors for athero-
sclerosis (age, gender, smoking status, hypertension, dia-
betes, lipid profile, and carotid intima-media thicknessJournal of Cardiovascular Magnetic Resonance 2009, 11:10 http://www.jcmr-online.com/content/11/1/10
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measures (IMT)). Any patient who had at least two risk
factors for atherosclerosis (not including older age) was
recruited into the imaging study. The following criteria
were used to determine a positive risk factor: A mean IMT
> 1.1 mm, or a focal structure that encroached into the
arterial lumen by at least 0.6 mm represented a positive
IMT. A patient was considered to be hypertensive if either
systolic or diastolic blood pressure was greater than 140
and 100 mm HG respectively or the patient was on anti-
hypertensive medication. A patient was considered to be
hypercholesteromic if total cholesterol was > 200 mg/dl,
and LDL was > 160 mg/dl or if the patient was on a statin.
Fasting plasma glucose levels of more than 126 mg/dl on
two or more tests on different days or HbA1c > 6.5 indi-
cated diabetes.
MR system
MR was performed on a 1.5T Siemens Sonata (Siemens
Medical Solutions, Erlangen, Germany) whole body scan-
ner running a Numaris 4.0 operating system. This scanner
has a maximum gradient amplitude of 40 mT/m and slew
rate of 200 mT/m/ms. The integrated body coil was used
for transmission while a custom built 4-channel carotid
array was used for signal reception of the carotid images.
Aortic images were obtained using a 6 channel cardiac coil
in conjunction with the spine array for signal reception.
Carotid imaging protocol
Twelve non-overlapping cross sectional slices starting at
and extending below the left carotid bifurcation were
obtained using a the rapid extended coverage double
inversion recovery turbo spin echo black blood (REX)
pulse sequence developed previously [21]. Proton density
images were obtained using the following parameters.
Twelve slices were acquired simultaneously with a repeti-
tion time of 2130 ms and an echo time of 5.6 ms. A field
of view of 12 × 12 cm was used in conjunction with a
receiver bandwidth of 488 Hz/pixel, and a matrix size of
2562, a turbo factor of 15 and 2 signal averages. The slice
thickness was 3 mm. Fat suppression was achieved using
a chemical shift selective pulse. Acquisition time was
approximately 3 minutes for each 12 slices imaged. Car-
diac or peripheral gating was not used for carotid image
acquisition [20]. Data from the left and right carotid arter-
ies were combined and mean values used in the analyses.
Thoracic Aorta imaging protocol
Sixteen transverse images just above the level of the dia-
phragm (scout images obtained at end expiration) were
obtained using the REX sequence. The details of the REX
sequence have been published previously[21]. All aortic
images were obtained using cardiac gating. The imaging
parameters were similar to those used for carotid imaging
except as follows: 16 slices were acquired simultaneously
with a field of view used of 20 cm2 and slice thickness of
5 mm. Acquisition time was approximately 3 minutes for
each 16 slices imaged. Respiratory gating was not used.
The images were of acceptable quality without the use of
respiratory gating and therefore it was deemed unneces-
sary. During the scan, if the image quality was deemed to
be poor due to respiratory motion, the patient was asked
to regulate his/her breathing and the scan was repeated.
The use of multiple signal averages also reduced the effect
of respiratory motion on the image.
MR imaging analysis
After acquisition, MR images were transferred to a dedi-
cated workstation for analysis. Each image was qualita-
tively assessed on a scale of 1–5, in four categories (overall
image quality, flow suppression, artifacts, and vessel wall
delineation) with 5 representing the best quality, by an
expert observer (KBW, 5 years MR imaging experience) as
described in earlier studies [20]. All images with an image
quality of 1 or 2 in any of the four categories were
excluded from analysis. On all images that were deemed
to be of sufficient quality, the inner and outer vessel wall
boundaries were manually traced for both the common
carotids and thoracic descending aorta. Mean lumen
diameter, vessel diameter, lumen area, wall area, total ves-
sel area, mean wall thickness and standard deviation of
wall thickness for each slice were calculated based on the
contours drawn by the expert observer using a customized
software program (Vessel Mass Software, Leiden Univer-
sity Medical Center, The Netherlands). The lumen diame-
ter and outer vessel diameter were measured as follows:
The centroid of the lumen and outer wall boundary were
determined based on the contours drawn by the observer.
Radial lines were drawn at 4° increments through the cen-
troid towards the manually drawn contours. The length of
the radial lines extending to the lumen boundary deter-
mines the lumen diameter, and the length of the radial
line extending to the outer contours determines the outer
vessel diameter. The average of the 45 radial measures of
lumen diameter and outer vessel diameter are used for
analysis.
Wall thickness measurements were based on the Center-
line method, a previously used technique [28]. Using this
method, local wall thickness measurements were
obtained at 100 evenly spaced positions along the circum-
ference of the vessel wall. The standard deviation of the
100 measures of wall thickness provides the SD of the wall
thickness measures (eccentricity of plaque) for that partic-
ular slice. The MR imaging parameters measured are
shown in Figure 1. The normalized wall index (NWI) was
used to account for differences in size of the arteries
within each patient by normalizing to the outer vessel
area. Several studies have previously used the NWI in an
attempt to normalize wall areas for patient size [29,30].
The median number of slices available for each vascular
bed for each individual analyzed was 5. Figure 2 shows
sample MR images indicating plaques with varying stand-Journal of Cardiovascular Magnetic Resonance 2009, 11:10 http://www.jcmr-online.com/content/11/1/10
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ard deviation of wall thickness in carotid arteries. Wall
volumes were not measured as only 2D imaging was per-
formed and measures of average wall area and total vol-
ume reflect the same parameter (i.e. wall volume =
average wall area * number of slices).
The individual performing the image contouring (KBW)
was blinded to all patient history and demographic infor-
mation including presence or absence of prior MACE. The
order of patient presentation for contouring was rand-
omized.
Statistical Analysis
The cohort was stratified by the presence of prior MACE
defined as stroke (including transient ischemic attacks) or
coronary artery disease (including acute coronary syn-
drome, history of myocardial infarction, history of coro-
nary artery bypass surgery, or history of percutaneous
intervention). Demographic characteristics, traditional
CVD risk factors, and CMR measures of the carotid arteries
and thoracic descending aorta for the study population
were summarized separately for those with and without
prior MACE. Non-normally distributed variables were log
transformed. Continuous variables were summarized
using means, and geometric means for non-normally dis-
tributed variables, with differences across presence of
prior MACE assessed using Student's t-tests. Dichotomous
variables were summarized as proportions and compared
using Chi-square tests.
For all analyses, MR measures of the carotid arteries and
thoracic descending aorta were analyzed separately. The
prevalence of prior MACE was correlated by tertile of each
MR measure. Trends in prevalence across tertiles were cal-
culated by modeling the median MR measure for each ter-
tile as an independent continuous variable. The
prevalence odds ratio for prior MACE associated with each
MR measure, modeled as a continuous variable, was also
computed. Initially, this association was determined after
age and sex adjustment. Subsequent models included
additional adjustment for traditional CVD risk factors
including history of smoking, body mass index, hyperten-
sion and diabetes mellitus. Odds ratios are presented for
a one standard deviation higher MR measure.
Next, the area under the receiver operating characteristic
curves (AUC) for discriminating prior MACE was com-
puted. An initial model assessed the discriminatory value
of age and sex. A subsequent model included age and sex
MR imaging parameters measured for carotids and thoracic  aorta Figure 1
MR imaging parameters measured for carotids and 
thoracic aorta. The red line indicates the measure of the 
lumen diameter; the teal line represents the vessel diameter, 
the green line represents the wall thickness. The area 
enclosed by the blue contour represents the lumen area and 
the area enclosed by the orange contour represents the total 
vessel area. The difference between the total vessel area and 
the lumen area provides the wall area. The normalized wall 
index is determined by the ratio of the wall area to the total 
vessel area. The top right panel shows the contours on a 
sample carotid image.
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Sample MR Images showing individuals with varying SD wall thickness of carotid arteries Figure 2
Sample MR Images showing individuals with varying SD wall thickness of carotid arteries. (Panel A shows an indi-
vidual with high SD of wall thickness, Panel B shows medium SD of wall thickness and Panel C shows low SD of wall thick-
ness).* indicates lumen. Arrow indicates plaque.
** *
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Table 1: Characteristics of study participants by cardiovascular disease status.
MACE
Yes
(n = 53)
No
(n = 142)
P-value
Demographics
Age, years 65.3 (1.1) 60.1 (0.6) < 0.001
Male, % 73.6 59.2 0.063
Ever smoking, % 54.7 57.0 0.771
Hypertension, % 54.7 43.0 0.056
On statin treatment % 82.0 67.2 0.081
History of diabetes mellitus% 41.5 24.2 0.020
Body mass index, kg/m2 26.9 (0.7) 26.9 (1.1) 0.993
MRI parameter-Carotids
Lumen diameter†, mm 6.64 (6.43 – 6.84) 6.52 (6.39 – 6.65) 0.351
Vessel diameter†, mm 8.72 (8.47 – 8.98) 8.41 (8.26 – 8.57) 0.042
Wall thickness†, mm 1.03 (0.97 – 1.09) 0.93 (0.91 – 0.96) 0.001
SD wall thickness, mm 0.137 (0.008) 0.102 (0.004) < 0.001
Lumen area†, mm2 0.348 (0.327 – 0.370) 0.335 (0.322 – 0.348) 0.332
Total vessel area†, mm2 0.60 (0.57 – 0.64) 0.56 (0.54 – 0.58) 0.038
Wall area†, mm2 0.25 (0.23 – 0.27) 0.22 (0.21 – 0.23) 0.003
Normalized wall index 0.416 (0.008) 0.396 (0.004) 0.015
MRI parameter-Thoracic aorta
Lumen diameter, mm 22.1 (0.3) 22.0 (0.2) 0.833
Vessel diameter, mm 25.5 (0.4) 25.1 (0.2) 0.385
Wall thickness†, mm 1.63 (1.53 – 1.73) 1.50 (1.46 – 1.55) 0.009
SD wall thickness†, mm 0.186 (0.151 – 0.228) 0.139 (0.125 – 0.155) 0.009
Lumen area, mm2 3.90 (0.12) 3.87 (0.07) 0.801
Total vessel area, mm2 5.17 (0.16) 5.01 (0.09) 0.345
Wall area†, mm2 1.21 (1.12 – 1.32) 1.11 (1.07 – 1.15) 0.027
Normalized wall index 0.244 (0.006) 0.229 (0.003) 0.016
Numbers in table represent mean (standard deviation), †geometric mean (95% confidence interval) or percentageJournal of Cardiovascular Magnetic Resonance 2009, 11:10 http://www.jcmr-online.com/content/11/1/10
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Table 2: Prevalence and adjusted odds ratios of MACE associated with each tertile of magnetic resonance imaging parameters.
Tertile of Magnetic Resonance Imaging Parameters
Tertile 1 Tertile 2 Tertile 3 P-trend
Carotids
Lumen diameter, range in mm < 6.20 6.20 – 6.83 > 6.83
Prevalence of MACE 20.0 33.9 27.7 0.325
Vessel diameter, range in mm < 8.15 8.15 – 8.86 > 8.86
Prevalence of MACE 16.9 27.7 36.9 0.011
Wall thickness, range in mm < 0.891 0.891 – 1.00 > 1.00
Prevalence of MACE 18.5 23.1 40.0 0.007
Standard deviation wall thickness, range in mm < 0.088 0.088 – 0.127 > 0.127
Prevalence of MACE 12.9 29.0 43.6 < 0.001
Lumen area, range in mm2 < 0.302 0.302 – 0.369 > 0.369
Prevalence of MACE 20.0 32.3 29.2 0.238
Total vessel area, range in mm2 < 0.522 0.522 – 0.619 > 0.619
Prevalence of MACE 16.9 27.7 36.9 0.011
Wall area, range in mm2 < 0.204 0.204 – 0.244 > 0.244
Prevalence of MACE 15.4 27.7 38.5 0.004
Normalized wall index, range < 0.382 0.382 – 0.418 > 0.418
Prevalence of MACE 24.6 20.0 36.9 0.117
Thoracic aorta
Lumen diameter, range in mm < 21.1 21.2 – 23.2 > 23.2
Prevalence of MACE 26.2 26.2 29.2 0.693
Vessel diameter, range in mm < 24.3 24.3 – 26.3 > 26.3
Prevalence of MACE 24.6 27.7 29.2 0.555Journal of Cardiovascular Magnetic Resonance 2009, 11:10 http://www.jcmr-online.com/content/11/1/10
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and traditional CVD risk factors with final models includ-
ing age, sex, traditional CVD risk factors and each MR
imaging measure, separately. The discriminatory ability of
these models to detect those with prior MACE (i.e., the
AUC) was compared following the method of DeLong,
DeLong and Clarke-Pearson for correlated data[31] Statis-
tical analyses were performed using Stata version 10.0
(Stata Incorporated, College Station, TX).
Results
Characteristics of study participants by prior MACE are
provided in Table 1. Participants with prior MACE were
older, and had a history of diabetes mellitus.
Carotid imaging
Vessel diameter, wall thickness, plaque eccentricity
(standard deviation of wall thickness), wall area, total ves-
sel area, and normalized wall index were each signifi-
cantly higher for individuals with prevalent prior MACE
compared to those without (Table 1). Prior MACE was
more common at each higher tertile of vessel diameter,
wall thickness, plaque eccentricity, total vessel area, and
wall area (Table 2).
After age and sex adjustment, the prevalence odds ratios
for prior MACE for each one standard deviation increase
(0.19 mm for wall thickness, and 0.05 mm for plaque
eccentricity) were 1.46 (95% CI: 1.03 – 2.06) and 1.66
(95% CI: 1.17 – 2.37), respectively (Table 3). After further
adjustment for ever-smoking status, body mass index,
hypertension and diabetes mellitus, the odds ratios for
one standard deviation higher wall thickness (0.05 mm)
became 1.80 (95% CI: 1.18–2.76).
The AUC for discriminating prior MACE using age and sex
alone was 0.71, which increased to 0.73 by the additional
inclusion of traditional CVD risk factors (Table 4). The
only MR parameter that significantly improved the AUC
was a measure of plaque eccentricity, i.e. the standard
deviation of wall thickness; the AUC then became 0.79 (p-
value = 0.05 compared to the age, sex, traditional risk fac-
tor model). Receiver operating characteristic curves for
discriminating prior MACE for models comprised of age
and sex, age, sex and traditional CVD risk factors, and
these factors plus plaque eccentricity is also shown in Fig-
ure 3.
Wall thickness, range in mm < 1.43 1.43 – 1.63 > 1.63
Prevalence of MACE 18.5 27.7 35.4 0.032
Standard deviation wall thickness, range in mm < 0.123 0.123 – 0.199 > 0.199
Prevalence of MACE 18.8 21.9 42.2 0.004
Lumen area, range in mm2 < 3.51 3.51 – 4.22 > 4.22
Prevalence of MACE 26.2 26.2 29.2 0.693
Total vessel area, range in mm2 < 4.65 4.65 – 5.47 > 5.47
Prevalence of MACE 24.6 27.7 29.2 0.555
Wall area, range in mm2 < 1.05 1.05 – 1.25 > 1.25
Prevalence of MACE 21.5 26.2 33.9 0.112
Normalized wall index, range < 0.214 0.214 – 0.241 > 0.241
Prevalence of MACE 18.5 24.6 38.5 0.011
Abbreviations: mm – millimeter, MACE: prior major cardiovascular and cerebrovascular events
Table 2: Prevalence and adjusted odds ratios of MACE associated with each tertile of magnetic resonance imaging parameters. Journal of Cardiovascular Magnetic Resonance 2009, 11:10 http://www.jcmr-online.com/content/11/1/10
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Thoracic aorta imaging
Wall thickness, plaque eccentricity, wall area, and normal-
ized wall index of the thoracic aorta were each signifi-
cantly higher among individuals with prior MACE (Table
1; bottom panel). Prior MACE was also more common at
each progressively higher tertile of wall thickness, plaque
eccentricity, and normalized wall index (Table 2; bottom
panel).
Modeled as a continuous variable, plaque eccentricity and
normalized wall index showed the highest, albeit non-sig-
nificant, increase in the prevalence odds ratios of prior
MACE after multivariate adjustment (Table 3; bottom
panel). The bottom panel of Table 4 shows the AUC for
discriminating prior MACE using models incorporating
age, sex, traditional CVD risk factors and MR parameters.
Compared to results of a model including age, sex, and
traditional CVD risk factors, incorporating MR imaging
data did not significantly improve the ability to discrimi-
nate prior MACE.
Discussion
The results of the current study of non invasive imaging of
two vascular beds (carotid arteries and the thoracic
descending aorta), obtained during a single imaging
examination, indicate that MR imaging parameters of
Table 3: Odds ratios (95% confidence intervals) for MACE associated with one standard deviation higher magnetic resonance imaging 
parameters of carotid arteries, adjusted for age, sex, history of ever smoking, body mass index, hypertension and diabetes mellitus.
MRI parameter Age and sex adjusted Multivariate adjusted
Carotids
Lumen diameter, 0.77 mm 1.05 (0.75 – 1.47) 1.03 (0.71 – 1.48)
Vessel diameter, 0.95 mm 1.21 (0.85 – 1.71) 1.18 (0.80 – 1.72)
Wall thickness, 0.19 mm 1.46 (1.03 – 2.06)* 1.47 (1.00 – 2.18)
Standard deviation wall thickness, 0.05 mm 1.66 (1.17 – 2.37)** 1.80 (1.18 – 2.76)**
Lumen area, 0.08 mm2 1.04 (0.75 – 1.44) 1.03 (0.72 – 1.46)
Total vessel area, 0.13 mm 1.20 (0.85 – 1.69) 1.18 (0.81 – 1.72)
Wall area, 0.06 mm2 1.36 (0.98 – 1.90) 1.36 (0.93 – 1.97)
Normalized wall index, 0.05 1.31 (0.94 – 1.82) 1.33 (0.92 – 1.93)
Thoracic aorta
MRI parameter Age and sex adjusted Multivariate adjusted
Lumen diameter, 2.44 mm 0.86 (0.60 – 1.24) 0.87 (0.57 – 1.31)
Vessel diameter, 2.67 mm 0.94 (0.66 – 1.34) 0.97 (0.65 – 1.44)
Wall thickness, 0.35 mm 1.23 (0.87 – 1.73) 1.27 (0.89 – 1.83)
Standard deviation wall thickness, 0.11 mm 1.36 (0.99 – 1.87) 1.42 (1.00 – 2.03)
Lumen area, 0.85 mm2 0.87 (0.60 – 1.25) 0.88 (0.58 – 1.33)
Total vessel area, 1.07 mm 0.95 (0.66 – 1.36) 0.99 (0.66 – 1.47)
Wall area, 0.35 mm2 1.15 (0.82 – 1.62) 1.22 (0.85 – 1.75)
Normalized wall index, 0.04 1.34 (0.95 – 1.90) 1.41 (0.96 – 2.07)
Abbreviations: MRI – magnetic resonance imaging
* p < 0.05, ** p < 0.01.Journal of Cardiovascular Magnetic Resonance 2009, 11:10 http://www.jcmr-online.com/content/11/1/10
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carotid arteries provide additional information with
respect to the differences in the nature of the atherosclero-
sis in subjects with traditional risk factors with and with-
out prior MACE. Most vascular MR studies typically focus
on only one arterial bed. The current study is unique in
the respect that both the carotids and thoracic descending
aorta were studied in the same patients during a single
examination. In agreement with previous studies [32-34],
individuals in our study with prior MACE were older, and
more likely to have diabetes[35] than those without prior
MACE.
In the current study, patients with prior MACE had signif-
icantly higher measures of plaque burden such as wall
thickness, wall area and plaque eccentricity (standard
deviation of wall thickness) but had similar lumen areas
compared to individuals without prior MACE. This indi-
cates potential positive "Glagov" remodeling [36] in both
the carotid arteries and the thoracic aorta among individ-
uals with prior MACE. Black blood MR imaging of athero-
sclerosis provides valuable information beyond the
luminogram provided by contrast angiography. Also we
showed that the standard deviation of the wall thickness
of atherosclerotic plaques in the carotid arteries, a meas-
ure of the eccentricity of the lesion, is independently asso-
ciated with increased odds of having prior MACE. The role
of carotid plaque eccentricity as a measure that predicts
previous MACE warrants further exploration with regard
to determining a potential mechanistic link.
Standard deviation of the wall thickness was not signifi-
cantly associated with prior MACE in the case of the tho-
racic aorta indicating that eccentric plaques in carotid
arteries may portend a greater risk than eccentric plaques
in the thoracic aorta.
Our study indicates that carotid MR imaging information
improves discrimination of prior MACE when incorpo-
Receiver operating characteristic curves for predicting cardi- ovascular disease using various models Figure 3
Receiver operating characteristic curves for predict-
ing cardiovascular disease using various models.
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P-value comparing AUC for age and sex with age, sex, and risk factors = 0.617
P-value comparing AUC for age and sex with full model = 0.044
P-value comparing AUC for age, sex, and risk factors with full model = 0.051
Risk factors include history of ever smoking, body mass index, hypertension and diabetes mellitus
Full model includes age, sex, risk factors, and standard deviation of wall thickness
Table 4: Area under the receiver operating characteristic curves
Model Carotids Thoracic aorta
1) Age and sex* 0.71 (0.64 – 0.78) 0.71 (0.64 – 0.78)
2) Age, sex and risk factors† 0.73 (0.65 – 0.79) 0.73 (0.65 – 0.79)
3) Age, sex, risk factors†, and lumen diameter 0.73 (0.66 – 0.80) 0.73 (0.65 – 0.79)
4) Age, sex, risk factors†, and vessel diameter 0.73 (0.66 – 0.80) 0.72 (0.65 – 0.79)
5) Age, sex, risk factors†, and wall thickness 0.75 (0.68 – 0.81) 0.74 (0.66 – 0.80)
6) Age, sex, risk factors†, and standard deviation wall thickness 0.79 (0.71 – 0.85) 0.74 (0.66 – 0.80)
7) Age, sex, risk factors†, and lumen area 0.73 (0.65 – 0.79) 0.72 (0.65 – 0.79)
8) Age, sex, risk factors†, and total vessel area 0.73 (0.66 – 0.80) 0.72 (0.65 – 0.79)
9) Age, sex, risk factors†, and wall area 0.74 (0.66 – 0.80) 0.73 (0.66 – 0.80)
10) Age, sex, risk factors†, and normalized wall index 0.74 (0.66 – 0.80) 0.74 (0.67 – 0.81)
Numbers in the table represent AUC and 95% confidence interval, Bold represents highest AUC value (See Figure 3 for p-value)
AUC – Area under the ROC curve
† Risk factors include history of ever smoking, body mass index, hypertension and diabetes mellitus.Journal of Cardiovascular Magnetic Resonance 2009, 11:10 http://www.jcmr-online.com/content/11/1/10
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rated into a model that includes age, sex and traditional
risk factors. Although not prospectively evaluated in our
study, the measures of atherosclerosis which show the
strongest associations with prior MACE (wall thickness
and plaque eccentricity) over and above traditional risk
factors may help explain some of the excess risk of future
events that these subjects are known to suffer from in clin-
ical observations. It appears from our study that carotid
MR imaging might provide more useful information than
thoracic aorta imaging for defining risk. This result corre-
lates with previous investigations that showed that
abdominal aortic imaging was more useful than thoracic
aorta imaging for atherosclerotic disease [37-39]. Previous
studies have also examined the effect of age and gender on
CMR measures of plaque burden and have also assessed
the inter and intra observer reproducibility of the imaging
techniques proposed here [40]. This study showed that
the CMR measurements of atherosclerotic plaque burden
were reproducible and that the CMR values for the mean
wall areas correlated strongly between carotid arteries and
aorta, suggesting a systemic distribution of disease. Simi-
lar to other clinical variables for cardiovascular diseases,
values for CMR parameters were found to be higher in
men than in women [40].
Limitations
One of the major limitations of this study is the cross-sec-
tional nature of the data obtained. Because this data was
not analyzed prospectively, any conclusions that can be
drawn from this study can only be causal associa-
tions[41]. Another limitation of the study is the fact that
all patients were followed up only by their respective pri-
mary care physicians and not as part of a research clinical
management protocol. Other limitations include non-
random selection of subjects, incomplete availability of
demographic information (i.e., race and ethnicity) and
lipid profiles. For the AUC analysis, some factors such as
ethnicity, lipid profiles, were not used for developing
models as this information was unavailable from all
patients included in this study. However, lipid profiles in
available patients were not significantly different between
those with and without prior MACE. Only risk factor data
obtained 3 months prior to or after the imaging scan was
used for the analysis. As no patients were scheduled for a
carotid endarterectomy, histological examinations of
plaques could not be performed. Another potential limi-
tation was that plaques were only classified based on bur-
den measured by proton density weighted imaging and
not their composition using multi contrast CMR and the
fact that only carotids and thoracic aorta images were ana-
lyzed. Another limitation of the study could include the
fact that only images of sufficiently high quality were
included for analysis and this selection of images could
introduce a selection bias into our dataset. Also, to reduce
partial voluming effects and artifacts caused in MR meas-
ures due to poor flow suppression (that may artificially
increase wall thickness measurements); only images from
the common carotid were used for analysis thereby elimi-
nating the carotid bifurcation, the region most susceptible
to such effects. The carotid bifurcation however is also the
location where atherosclerotic disease is more prevalent
and poor flow suppression may be related to the cardio-
vascular health of the arteries being observed as well. All
images were traced manually and could be subject to
observer bias as well. An automated tracing program
could have produced more robust and reproducible
results in terms of vessel wall traces. However, several
studies have shown that MR imaging is reproducible for
the quantification of vessel and plaque areas and can be
used confidently in studies, which require measuring
plaque size[24,25,42]. Imaging data from right and left
common carotid arteries were combined for analysis.
Although flow mechanics for each artery might be differ-
ent, an analysis of the left and right carotids produced
markedly similar results.
Conclusion
A greater plaque burden and plaque eccentricity in the
carotid arteries is prevalent among patients with risk fac-
tors and prior MACE compared to those with risk factors
only. Longitudinal studies are needed to further assess the
value of these and other MR measures of atherosclerosis as
prospective markers of future incident and recurrent
events. Clinical trials may use MR imaging in addition to
traditional risk factors to enrich their samples with sub-
jects at higher risk for cardiac events.
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